SCHEMBL20570535

SCHEMBL20570535

COC(=O)CCCCc1occc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.46
TSHR P16473 3/20 0.41
LMNA P02545 3/20 0.40
BACE1 P56817 1/20 0.40
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HDAC1 Q13547 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20570855 0.86 RXFP1 (0.41) LMNAMAPTALDH1A1
SCHEMBL20569194 0.81 PSMB8 (0.36) HPGDHTTKMT2AHSD17B10
SCHEMBL23948510 0.78 TNKS2 (0.37) HPGDLMNAMAPTALDH1A1HTT
Acetic Acid SCHEMBL23925788 0.77 ACHE (0.36) TSHR
SCHEMBL22184129 0.75 MTNR1A (0.50) HPGDKMT2A
SCHEMBL22184132 0.74 MTNR1A (0.44) KMT2A
SCHEMBL23948511 0.74 CHRM2 (0.38) TSHR
SCHEMBL23948513 0.74 MEN1 (0.33) HPGDTSHRLMNAALDH1A1KMT2A
SCHEMBL23948590 0.74 TAAR1 (0.39) HPGDTSHRLMNAALDH1A1KMT2A
SCHEMBL22184085 0.73 POLB (0.41) LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250152728-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-05-15 US disclosed
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-20230321267-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
US-20230321267-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
US-20230321267-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
US-11759526-B2 Method and molecules MEDIMMUNE, LLC (US) 2023-09-19 US disclosed
US-11759526-B2 Method and molecules MEDIMMUNE, LLC (US) 2023-09-19 US disclosed
US-11759526-B2 Method and molecules MEDIMMUNE, LLC (US) 2023-09-19 US disclosed
EP-4223319-A2 METHOD AND MOLECULES MedImmune, LLC (US) 2023-08-09 EP disclosed
US-11701427-B2 Diels-alder conjugation methods REGENERON PHARMACEUTICALS, INC. (US) 2023-07-18 US disclosed
EP-3630732-B1 METHOD AND MOLECULES MEDIMMUNE LLC (US) 2023-07-12 EP disclosed
EP-3630732-B1 METHOD AND MOLECULES MEDIMMUNE LLC (US) 2023-07-12 EP disclosed
CN-110650947-B Methods and molecules 免疫医疗有限责任公司 2023-05-12 CN disclosed
WO-2021211984-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2021-10-21 WO disclosed
US-20200206359-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-07-02 US disclosed
US-20200206359-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-07-02 US disclosed
EP-3630732-A1 METHOD AND MOLECULES Medimmune, LLC (US) 2020-04-08 EP disclosed
CN-110650947-A Methods and molecules 免疫医疗有限责任公司 2020-01-03 CN disclosed
WO-2018218093-A1 METHOD AND MOLECULES MEDIMMUNE, LLC (US) 2018-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250152728-A1 Method And Molecules PAICS, EPCAM, SQLE HPGD 668/4885TSHR 1084/4885LMNA 1762/4885
US-20200206359-A1 Method And Molecules PAICS, EPCAM, SQLE HPGD 668/4885TSHR 1084/4885LMNA 1762/4885
US-20230321267-A1 Method And Molecules PAICS, EPCAM, SQLE HPGD 668/4885TSHR 1084/4885LMNA 1762/4885
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS GLUL, TGM2, GLS HPGD 824/4885TSHR 2961/4885LMNA 2896/4885
US-11759526-B2 Method and molecules PAICS, EPCAM, SQLE HPGD 668/4885TSHR 1084/4885LMNA 1762/4885
US-11701427-B2 Diels-alder conjugation methods GLUL, TGM2, GLS HPGD 824/4885TSHR 2961/4885LMNA 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.